



MuTaLig COST ACTION CA15135
1st Annual meeting 2016
USI Lugano(CH), July 21-22 2016



Poster list

Num	Presenting author	Title
P_01	Akkari	Correlation of polyphenolic content with radical-scavenging capacity and anthelmintic effects of <i>Rubus ulmifolius</i> (Rosaceae) against gastrointestinal nematodes from sheep
P_02	Alian	Structural Systems Biology to Elucidating Targetable Inescapable Hubs
P_03	Artese	A multitarget approach for the <i>in silico</i> identification of bioactive compounds
P_04	Athanassopoulos	Polyamines, acidic retinoids, psoralens and taapeenin D analogs, conjugates and hybrids: natural products with potential multi-target activity
P_05	Bart	Discovery and development of new anti-invasive agents, an unmet clinical need
P_06	Bohac	Biological targets and rationale development of their modulators
P_07	Bolognesi	Novel tacrine-resveratrol hybrids as multi-target-directed ligands to combat Alzheimer's disease
P_08	Bolognesi	Crassiflorone-derived multi-target-directed ligands against trypanosomiasis
P_09	Campillo	From bitopic inhibitors to multitarget drugs to fight against Alzheimer's disease
P_10	Cristobal	Proteomic tools to predict nanodrug targeting and uptake
P_11	Danani	Investigating the constitutive activity of ghrelin receptor by molecular modeling
P_12	Danani	Drug-conjugation emerging properties: molecular insights
P_13	Di Marino	A Comprehensive Description of the Homo and Heterodimerization Mechanism of the Chemokine Receptors CCR5 and CXCR4
P_14	Dobricic	Design of acridine derivatives with potential antiproliferative activity based on multi-target action
P_15	Filipic	Targeting the PI3K/mTOR pathway as an antitumor strategy: 3D-QSAR study and design of dual PI3K/mTOR inhibitors



MuTaLig COST ACTION CA15135
1st Annual meeting 2016
USI Lugano(CH), July 21-22 2016



Num	Presenting author	Title
P_16	Gaspar	Benzopyrane as a valid scaffold for the development of multi-target ligands for neurodegenerative diseases
P_17	Guedes	Targeting the human 20S proteasome through a computational-based drug discovery approach
P_18	Kaczor	D2AAK1 as a potential multi-target antipsychotic
P_19	Korabecny	From acetylcholinesterase inhibitors to multitarget compounds for the treatment of Alzheimer's disease
P_20	Łażewska	<i>tert</i> -Amylphenoxy derivatives of 4-methyl- and homopiperidine ligands of histamine H3 receptor as Acetyl- and Butyrylcholinesterase inhibitors
P_21	Marmion	Crossing the interface between inorganic and organic chemistry, biology and pharmacology to generate innovative chemotherapeutics beyond those currently in use
P_22	Mikros	Heterocovariance based metabolomics as a powerful tool accelerating bioactive natural product discovery
P_23	Moraca	<i>In silico</i> approaches to target multiple sequences of G-quadruplex DNA
P_24	Padron	Lipidic anti- β -amino alcohols as selective inhibitors of CK1 ϵ
P_25	Pavon	Identification of Novel PPAR α and CB1 Receptor Ligands As Antiobesity Drugs
P_26	Schabikowski	Xanthine derivatives as MAO-B inhibitors and adenosine receptor antagonists
P_27	Shoemake	Identification of Lead Molecules Capable of the Simultaneous Agonism of the PPAR γ and PPAR α Subtypes for the Dual Management of Diabetes Mellitus and Dyslipidaemia
P_28	Starkov	Construction of De Novo All-Carbon Quaternary Stereocentres in Unbiased Acyclic Systems
P_29	Vacek	Electrochemical Sensing of Ligand Binding to Proteins Associated with Membranes
P_30	Veselinovic	Monte Carlo method based QSAR modeling of dihydrofolate reductase inhibition by selected pyrimidine derivatives
P_31	Yetik	New drug candidates targeting hydrogen sulfide